KONEXBiotech & Pharma140610

Ensol Biosciences

₩7,590▼ 5.13%2026-11-18 close
Market Cap
₩109.1B
Turnover
₩38,972,640
Volume
5.2K
Shares out.
14.4M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Re-Entry After the Phase 3 Miss

Ensol Biosciences is a KONEX-listed biotech running a second Phase 3 for P2K, a domestic Phase 3 for E1K and a renewed KOSDAQ transfer bid at the same time.

  1. 1

    For fiscal 2025, standalone revenue fell 98.3% and the operating loss widened 41.8%, according to FnGuide's company monitor.

  2. 2

    The P2K US Phase 3 recorded a p-value of 0.051 on the six-month composite endpoint, short of the significance threshold.

  3. 3

    Partner Spine Biopharma decided on a second Phase 3 and said it would pursue Accelerated Approval discussions with the FDA in parallel.

  4. 4

    E1K received MFDS approval for its Phase 3 trial plan in January 2026, and domestic distribution rights sit with Leaders Cosmetics.

  5. 5

    A KRW 5.0 billion third-party rights offering closed in June 2026, and the shares now trade below the 52-week low recorded as of September 30.

02

Business structure

Ensol Biosciences was founded in 2001 and listed on KONEX in 2018, and it is headquartered in Daejeon. The company develops short peptides that modulate protein-protein interactions.

It promotes its signal-path selective regulation (SSR) technology, which is meant to block only pathological signals, together with an AI-based candidate discovery platform.

Its core pipeline is P2K for degenerative disc disease, E1K for knee osteoarthritis and C1K for triple-negative breast cancer, followed by M1K for Alzheimer's disease and H1K, an oral obesity candidate.

Spine Biopharma of the United States leads global development of P2K. Yuhan ran the early domestic trials, and in 2018 Yuhan transferred exclusive rights to Spine Biopharma. According to earlier press reports, Ensol Biosciences receives 25% of the upfront payments and milestones under that arrangement.

In July 2024 the company signed a further license covering indications such as osteoarthritis, fibrosis and tumors, and its corporate history lists a total contract value of KRW 215.4 billion.

E1K is a synthetic peptide that selectively modulates the TGF-β1 signaling pathway to curb cartilage degeneration. The domestic Phase 3 targets 363 knee osteoarthritis patients and uses LG Chem's Synovian as the comparator.

Leaders Cosmetics holds the domestic distribution rights, and the company envisions a partner leading overseas trials after a license deal. The company says it first demonstrated efficacy through an animal osteoarthritis product.

Revenue remains small relative to the research effort. According to a data provider, revenue was split between animal pharmaceuticals at 77.26% and CMC synthesis and analytical services at 22.74%. The center of gravity is therefore license upfronts, milestones and royalties rather than product sales.

Unlike a large pharmaceutical company such as Yuhan with an established revenue base, results here depend on clinical outcomes and partner contracts.

03

Recent trends

As of 17:00 KST on October 27, 2026, the shares stood at KRW 8,330, up 6.39% on the day, for a market capitalization of KRW 119.8 billion. Trading value that day was KRW 34,526,240, which indicates thin liquidity. The September 30 close was KRW 9,800, and the 52-week range as of that date was KRW 8,810 to KRW 17,900. The current price is below that 52-week low.

For fiscal 2025, standalone revenue fell 98.3% from the prior year. FnGuide's company monitor attributed the drop to the absence of license revenue and limited sales of Jointvax. The operating loss widened 41.8%, while the net loss narrowed 69.9%. EBITDA was negative KRW 6.74 billion.

On August 1, 2025, Spine Biopharma released topline results from the SB-01 (P2K) US Phase 3. On the six-month NRS and ODI composite endpoint the SB-01 arm had a 67% success rate, but a high placebo response left the p-value at 0.051.

On August 4 the stock fell 14.86% to KRW 25,200 on KONEX, and the decline approached 40% over three sessions. Largest shareholder Smart & Growth's chief executive said in August that he had bought 400,000 shares on the open market.

In December 2025 Spine Biopharma's board settled on a second Phase 3 (Study-2) together with an FDA Accelerated Approval track. In January 2026 the E1K domestic Phase 3 trial plan was approved. In March 2026 the company decided to acquire shares of Leaders Cosmetics.

On June 19, 2026 it received payment for a KRW 5.0 billion third-party rights offering of 487,329 shares at KRW 10,260 each. The Bell reported that the offering and convertible bond conversions eliminated the capital impairment.

04

Outlook

The first item to watch is the P2K follow-up. In a July 2026 press report, Chief Executive Kim Hae-jin said Spine Biopharma was in Accelerated Approval discussions with the FDA and that talks could conclude in the second half of 2026 or the first half of 2027.

The FDA's official position has not been confirmed, and public detail on the design and timing of the second Phase 3 is limited. The company also says it intends to file for the second Phase 3 trial plan.

The second item is the domestic E1K Phase 3. The primary endpoint tests non-inferiority to the active comparator on pain and function at six months. Secondary endpoints cover pain, function and structural improvement at 12 months. According to press reports, 16 of a targeted 20 trial sites had been secured. Given enrollment and the dosing period, meaningful results will take time.

The third item is the KOSDAQ transfer listing. The company passed a technology evaluation in September 2022 but withdrew its preliminary listing application in December 2023.

It switched its lead underwriter from Hana Securities to Shinhan Investment Corp., and The Bell reported a one-track strategy that leads with P2K. As of October 27, 2026, no technology evaluation result had been confirmed.

The fourth item is revenue recognition. The company has set a 2026 revenue target of KRW 10 billion, made up of a KRW 6 billion Spine Biopharma upfront payment and a KRW 4 billion upfront payment for E1K domestic distribution rights.

Whether these amounts have been booked as revenue must be checked in quarterly filings. M1K and H1K are early-stage and were reported as unable to support near-term results. Cash burn and the need for further financing remain ongoing checkpoints.

05

Bull factors

Follow-up trial and accelerated pathway

Spine Biopharma said the SB-01 arm showed a 67% composite success rate and that safety was confirmed. It attributed the miss to abnormally high placebo responses at some sites. It chose to design a second Phase 3 to address this while pursuing Accelerated Approval talks.

Press reports note that apart from pain management there is no disease-modifying treatment for degenerative disc disease, so unmet demand is large.

E1K Phase 3 and upfront payment structure

E1K entered late-stage development with its domestic Phase 3 approval in January 2026. The domestic distribution deal with Leaders Cosmetics gives a structure that can share part of the development cost. The company plans to have a license partner run overseas trials.

Industry reports said talks with multiple global drug makers were under way, but no contract has been confirmed.

Capital impairment cleared and major shareholder support

Press reports said the June 2026 offering of KRW 5.0 billion and convertible bond conversions cleared the capital impairment. Total assets at the end of 2025 were in the KRW 31.6 billion range and total liabilities were KRW 18.1 billion.

Smart & Growth, the largest shareholder, bought on the open market after the Phase 3 readout, and filings show it took part in the offering. This can be read neutrally as a major shareholder participating in funding.

06

Bear factors

Clinical miss on the lead asset

P2K missed its primary endpoint in the US Phase 3, following an earlier Phase 2b conducted by Yuhan that did not show efficacy over placebo. The placebo-response explanation is the interpretation of the company and its partner, and the same problem could recur in further trials.

Subgroup findings are post hoc, so how regulators will treat them is uncertain. A second Phase 3 will require additional cost and time.

Revenue gap and continuing losses

Standalone revenue for fiscal 2025 fell 98.3% and the operating loss widened 41.8%. Revenue swings heavily with the presence or absence of license upfront payments. Sales of animal pharmaceuticals and CMC services are small and did not cover fixed costs. Whether the KRW 10 billion 2026 revenue target is actually recognized has to be confirmed through filings.

Listing-transfer uncertainty and thin liquidity

The company withdrew its preliminary listing application in December 2023, and press reports cited reviewers' conservative view of new therapeutic modalities as an obstacle. As of October 27, 2026, no technology evaluation result had been confirmed.

KONEX trading is thin, with the day's trading value at only KRW 34,526,240. After the Phase 3 miss, the largest shareholder said trading had nearly stopped.

07

Risk factors

Macro and market

Tighter interest rates and weaker biotech sentiment can worsen funding conditions for clinical-stage companies. KONEX trades thinly, so even small volumes can move the price sharply. In August 2025 the stock hit its daily price limit on consecutive days. The wide gap between the 52-week high and low also reflects this volatility.

Clinical and regulatory

It has not been confirmed whether the FDA will accept Accelerated Approval. Filing the second Phase 3 plan, enrolling patients and reporting results could take a long time.

The E1K domestic Phase 3 has non-inferiority to an active comparator as its primary goal, and results that differ from expectations could affect license talks. The approach of modulating signaling pathways with peptides has few commercial precedents, adding uncertainty to regulatory judgments.

Financial and governance

With operating losses continuing, additional funding may be needed to cover research costs. Third-party offerings and convertible bond conversions dilute existing shareholders. Changes in holdings by the largest shareholder or specific investors can affect supply and demand.

It also needs to be monitored whether the acquisition of shares in an outside company translates into business results.

08

Overall view

Ensol Biosciences is a clinical-stage peptide company with a thin revenue base, and a large share of its value is tied to clinical results for P2K and E1K. The August 2025 Phase 3 miss raised uncertainty around its lead asset, and fiscal 2025 results showed falling revenue and a wider operating loss.

On the other hand, the partner's decision on a second Phase 3, the E1K domestic Phase 3 approval and the clearing of capital impairment are cited as evidence of progress. The KOSDAQ transfer listing is an open item, since the company has a withdrawal history and no result had been confirmed as of October 27, 2026.

The price of KRW 8,330 is below the 52-week low recorded as of September 30, and small trading value imposes significant liquidity constraints. Items to monitor are the outcome of FDA discussions, E1K enrollment progress, whether 2026 revenue is recognized and any further financing. This report is for informational purposes only, and investment decisions are left to the reader.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. markets.hankyung.com
  3. alphasquare.co.kr
  4. goinsider.kr
  5. m.dailypharm.com
  6. sedaily.com
  7. ebn.co.kr
  8. dailymedi.com
  9. v.daum.net
  10. newsway.co.kr
  11. thebell.co.kr
  12. bloter.net
  13. hellodd.com
  14. edaily.co.kr
  15. pharm.edaily.co.kr
  16. hitnews.co.kr
  17. ensolbio.co.kr
  18. ensolbio.co.kr

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis